{"id":"W2047269416","doi":"10.1007/s00280-014-2474-0","title":"A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Everolimus; Medicine; Panitumumab; Internal medicine; Regimen; Mucositis; Refractory (planetary science); Fluorouracil; Sirolimus; Oxaliplatin; Colorectal cancer; Gastroenterology; Oncology; Toxicity; Surgery; Chemotherapy; Cancer; KRAS","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001241034,0.001665558,0.002663089,0.0005051303,0.0004963808,0.001148455,0.0008654259,0.001316409,0.003779076],"category_scores_gemma":[0.0007905994,0.0006973619,0.002026875,0.0005153293,0.001046443,0.001164384,0.0003813415,0.004499998,0.0009106246],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001115055,"about_ca_system_score_gemma":0.001495867,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00138911,"about_ca_topic_score_gemma":0.00424696,"domain_scores_codex":[0.999638,0.0001380247,0.00001865638,0.00007840734,0.00002320724,0.00010366],"domain_scores_gemma":[0.9994593,0.00008614808,0.00006561649,0.00004369954,0.00002239933,0.0003228343],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8566701,0.03100509,0.002768261,0.000564179,0.001828932,0.0002347252,0.0002332967,0.003200994,0.02478062,0.000399775,0.004226932,0.07408704],"study_design_scores_gemma":[0.7059111,0.2808736,0.005769024,0.00002966453,0.0006543185,0.0002283007,0.00005405495,0.001041921,0.002351582,0.0002318618,0.002822469,0.00003206415],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897375,0.003062102,0.0005940179,0.001184728,0.0003467957,0.001317213,0.001190008,0.0001353414,0.002432327],"genre_scores_gemma":[0.9870984,0.002280773,0.001846817,0.001147362,0.0002453082,0.001439205,0.002506351,0.00004772175,0.003388062],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003779076,"threshold_uncertainty_score":0.01264226,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008706825118384477,"score_gpt":0.2963860966402916,"score_spread":0.2876792715219071,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}